Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bicara Therapeutics Inc. (BCAX)
NASDAQ:BCAX
RESEARCH TOOLSreports
Holding BCAX?
Track your performance easily
BCAX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$18.33 - $28.09
Previous Close$23.6
Volume178.23K
Average Volume (3M)492.55K
Market Cap
$1.28B
Enterprise Value$1.08B
Total Cash (Recent Filing)$203.85M
Total Debt (Recent Filing)$300.00K
Price to Earnings (P/E)―
Beta-2.36
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding51,760,925
10 Day Avg. Volume306,184
30 Day Avg. Volume492,551
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$43.33Price Target Upside81.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Ownership Overview
37.40% Insiders
1.06% Other Institutional Investors
61.39% Public Companies and
Individual Investors
BCAX FAQ
What was Bicara Therapeutics Inc.’s price range in the past 12 months?
Bicara Therapeutics Inc. lowest stock price was $18.33 and its highest was $28.09 in the past 12 months.
What is Bicara Therapeutics Inc.’s market cap?
Currently, no data Available
When is Bicara Therapeutics Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Bicara Therapeutics Inc.’s earnings last quarter?
Currently, no data Available
Is Bicara Therapeutics Inc. overvalued?
According to Wall Street analysts Bicara Therapeutics Inc.’s price is currently Undervalued.
Does Bicara Therapeutics Inc. pay dividends?
Bicara Therapeutics Inc. does not currently pay dividends.
What is Bicara Therapeutics Inc.’s EPS estimate?
Bicara Therapeutics Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bicara Therapeutics Inc. have?
Bicara Therapeutics Inc. has 54,385,925 shares outstanding.
What happened to Bicara Therapeutics Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bicara Therapeutics Inc.?
Currently, no hedge funds are holding shares in BCAX
---
Bicara Therapeutics Inc. Stock Smart Score
Company Description
Bicara Therapeutics Inc.
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Our lead program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, or HNSCC, where there remains a significant unmet need. We intend to initiate a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab as a first-line therapy in recurrent/metastatic HNSCC excluding HPV-positive patients with oropharyngeal squamous cell carcinoma late in the fourth quarter of 2024 or early in the first quarter of 2025.
---
BCAX Stock 12 Month Forecast
Average Price Target
$43.33
▲(81.91% Upside)
Technical Analysis
Best Analysts Covering BCAX
1 Year
1 Year Success Rate
1/1 ratings generated profit
1 Year Average Return
+4.60%
initiated a buy rating last month
Copying Stephen Willey's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +4.60% per trade.
---